KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Shares Issued (2016 - 2025)

Regeneron Pharmaceuticals has reported Shares Issued over the past 17 years, most recently at $503.5 million for Q4 2025.

  • Quarterly results put Shares Issued at $503.5 million for Q4 2025, up 453.91% from a year ago — trailing twelve months through Dec 2025 was $635.9 million (down 56.6% YoY), and the annual figure for FY2025 was $635.9 million, down 56.6%.
  • Shares Issued for Q4 2025 was $503.5 million at Regeneron Pharmaceuticals, up from $40.3 million in the prior quarter.
  • Over the last five years, Shares Issued for REGN hit a ceiling of $821.4 million in Q3 2021 and a floor of $31.5 million in Q2 2025.
  • Median Shares Issued over the past 5 years was $303.9 million (2022), compared with a mean of $321.9 million.
  • Peak annual rise in Shares Issued hit 453.91% in 2025, while the deepest fall reached 92.8% in 2025.
  • Regeneron Pharmaceuticals' Shares Issued stood at $542.7 million in 2021, then plummeted by 31.34% to $372.6 million in 2022, then dropped by 19.22% to $301.0 million in 2023, then crashed by 69.8% to $90.9 million in 2024, then soared by 453.91% to $503.5 million in 2025.
  • The last three reported values for Shares Issued were $503.5 million (Q4 2025), $40.3 million (Q3 2025), and $31.5 million (Q2 2025) per Business Quant data.